AU2020411442B2 - Aqueous suspension composition containing sirolimus or salt thereof - Google Patents
Aqueous suspension composition containing sirolimus or salt thereofInfo
- Publication number
- AU2020411442B2 AU2020411442B2 AU2020411442A AU2020411442A AU2020411442B2 AU 2020411442 B2 AU2020411442 B2 AU 2020411442B2 AU 2020411442 A AU2020411442 A AU 2020411442A AU 2020411442 A AU2020411442 A AU 2020411442A AU 2020411442 B2 AU2020411442 B2 AU 2020411442B2
- Authority
- AU
- Australia
- Prior art keywords
- sirolimus
- salt
- composition
- aqueous suspension
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019237226 | 2019-12-26 | ||
| JP2019-237226 | 2019-12-26 | ||
| PCT/JP2020/048738 WO2021132565A1 (ja) | 2019-12-26 | 2020-12-25 | シロリムスまたはその塩を含有する水性懸濁組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2020411442A1 AU2020411442A1 (en) | 2022-06-23 |
| AU2020411442B2 true AU2020411442B2 (en) | 2026-02-12 |
Family
ID=76575568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020411442A Active AU2020411442B2 (en) | 2019-12-26 | 2020-12-25 | Aqueous suspension composition containing sirolimus or salt thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230055121A1 (https=) |
| EP (1) | EP4082544A4 (https=) |
| JP (2) | JP7682103B2 (https=) |
| KR (1) | KR20220122612A (https=) |
| CN (2) | CN118340726A (https=) |
| AU (1) | AU2020411442B2 (https=) |
| CA (1) | CA3162626A1 (https=) |
| TW (1) | TWI871406B (https=) |
| WO (1) | WO2021132565A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116942607A (zh) * | 2023-01-13 | 2023-10-27 | 杭州微致生物科技有限公司 | 一种西罗莫司混悬液 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009023877A2 (en) * | 2007-08-16 | 2009-02-19 | Macusight, Inc. | Formulations for treatment of ocular diseases or conditions |
| CN106420607A (zh) * | 2016-11-02 | 2017-02-22 | 北京诺康达医药科技有限公司 | 一种西罗莫司纳米混悬剂及其制备方法 |
| CN107334734A (zh) * | 2017-07-10 | 2017-11-10 | 浙江大学 | 一种西罗莫司或其衍生物的眼用制剂 |
| US20180193320A1 (en) * | 2017-01-06 | 2018-07-12 | Palvella Therapeutics Llc | ANYHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA924953B (en) | 1991-07-25 | 1993-04-28 | Univ Louisville Res Found | Method of treating ocular inflammation |
| US8663639B2 (en) * | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| ES2667945T3 (es) | 2007-10-08 | 2018-05-16 | Aurinia Pharmaceuticals Inc. | Composiciones oftálmicas que comprenden inhibidores de calcineurina o Inhibidores de mTOR |
| CN105073112B (zh) | 2013-03-13 | 2017-12-29 | 参天制药株式会社 | 睑板腺功能障碍的治疗剂 |
| JP6279395B2 (ja) * | 2014-05-01 | 2018-02-14 | 東亜薬品株式会社 | ブリンゾラミド懸濁性点眼液組成物の製造方法 |
| CN105833344B (zh) * | 2016-04-26 | 2019-04-26 | 青岛慧生惠众生物科技有限公司 | 一种可注射水凝胶在制备眼内填充物中的应用 |
| US20200261427A1 (en) * | 2019-02-20 | 2020-08-20 | Al Therapeutics, Inc. | Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders |
-
2020
- 2020-12-25 US US17/784,327 patent/US20230055121A1/en active Pending
- 2020-12-25 WO PCT/JP2020/048738 patent/WO2021132565A1/ja not_active Ceased
- 2020-12-25 CA CA3162626A patent/CA3162626A1/en active Pending
- 2020-12-25 JP JP2021567672A patent/JP7682103B2/ja active Active
- 2020-12-25 CN CN202410500671.8A patent/CN118340726A/zh active Pending
- 2020-12-25 EP EP20905210.9A patent/EP4082544A4/en active Pending
- 2020-12-25 AU AU2020411442A patent/AU2020411442B2/en active Active
- 2020-12-25 KR KR1020227018715A patent/KR20220122612A/ko not_active Ceased
- 2020-12-25 CN CN202080089390.8A patent/CN114845714B/zh active Active
- 2020-12-25 TW TW109146288A patent/TWI871406B/zh active
-
2025
- 2025-05-13 JP JP2025080159A patent/JP2025111828A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009023877A2 (en) * | 2007-08-16 | 2009-02-19 | Macusight, Inc. | Formulations for treatment of ocular diseases or conditions |
| CN106420607A (zh) * | 2016-11-02 | 2017-02-22 | 北京诺康达医药科技有限公司 | 一种西罗莫司纳米混悬剂及其制备方法 |
| US20180193320A1 (en) * | 2017-01-06 | 2018-07-12 | Palvella Therapeutics Llc | ANYHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE |
| CN107334734A (zh) * | 2017-07-10 | 2017-11-10 | 浙江大学 | 一种西罗莫司或其衍生物的眼用制剂 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021132565A1 (ja) | 2021-07-01 |
| TWI871406B (zh) | 2025-02-01 |
| KR20220122612A (ko) | 2022-09-02 |
| JP7682103B2 (ja) | 2025-05-23 |
| CA3162626A1 (en) | 2021-07-01 |
| AU2020411442A1 (en) | 2022-06-23 |
| JPWO2021132565A1 (https=) | 2021-07-01 |
| US20230055121A1 (en) | 2023-02-23 |
| CN118340726A (zh) | 2024-07-16 |
| EP4082544A4 (en) | 2024-01-10 |
| JP2025111828A (ja) | 2025-07-30 |
| TW202135806A (zh) | 2021-10-01 |
| CN114845714A (zh) | 2022-08-02 |
| CN114845714B (zh) | 2024-05-14 |
| EP4082544A1 (en) | 2022-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3096740B1 (en) | Pharmaceutical composition comprising brinzolamide | |
| EA034839B1 (ru) | Офтальмологический раствор | |
| KR102876762B1 (ko) | 에피나스틴 함유 점안액 | |
| US20180169079A1 (en) | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound | |
| US5556848A (en) | Ophthalmic suspension containing diflupredonate | |
| EP3718535B1 (en) | Ophthalmic compositions containing a nitric oxide releasing prostamide | |
| JP6903448B2 (ja) | ドルゾラミドとブリモニジンを含む医薬組成物 | |
| AU2020411442B2 (en) | Aqueous suspension composition containing sirolimus or salt thereof | |
| US6274609B1 (en) | Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative | |
| CN111741755B (zh) | 肠胃外制剂及其用途 | |
| WO2010119942A1 (ja) | レボカバスチン懸濁型点眼剤 | |
| KR20220038443A (ko) | 무균 안과용 수성 플루티카손 프로피오네이트 a형 나노결정 현탁액을 제조하는 방법 | |
| EP4631498A1 (en) | Eye drop-type pharmaceutical composition containing envogliflozin | |
| RU2842860C1 (ru) | Водная суспензионная композиция, содержащая сиролимус или его соль | |
| EP3689349A1 (en) | Drug containing pyridylaminoacetic acid compound | |
| EP2827838B1 (en) | Ophthalmic pharmaceutical composition containing a carbonic anhydrase inhibitor and method for the preparation thereof | |
| JP2022001606A (ja) | エピナスチン又はその塩を含有する水性組成物 | |
| JPH01313429A (ja) | 麦角アルカロイドを含有してなり緑内障を処置する眼用軟膏 | |
| KR101519673B1 (ko) | 피레녹신을 함유하는 현탁형 수성 액제 | |
| CA3220425A1 (en) | Pharmaceutical composition, and aprepitant injection and freeze-dried powder injection | |
| EA051764B1 (ru) | Офтальмологическая композиция, содержащая левофлоксацин и кеторолак, способ ее получения и ее применение | |
| KR20250059467A (ko) | 비결핵성 항산균 감염의 치료 방법 | |
| WO2024135837A1 (ja) | 組織移行性及び防腐効力を向上させるエピナスチン含有水性組成物 | |
| HK40018890B (en) | Ophthalmic compositions containing a nitric oxide releasing prostamide | |
| HK40018890A (en) | Ophthalmic compositions containing a nitric oxide releasing prostamide |